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Background: Medullary thyroid carcinoma (MTC) constitutes approximately 5 % of all thyroid cancers and carries a
worse prognosis than other differentiated thyroid cancers. Targeted therapies are being investigated for systemic
treatment of MTC. Ubiquitin-specific peptidase 39 (USP39) functions in pre-mRNA splicing as a component of the
U4/U6-U5 tri-snRNP and also participates in spindle checkpoint and cytokinesis. In this study, we aimed to evaluate
the potential role in MTC.
Methods: We used lentivirus-delivered short hairpin RNA (shRNA) to silence USP39 expression in one MTC cell line
TT. USP39 expression was detected by qPCR and Western blot. For functional analysis, MTT assay was performed to
evaluate the proliferation activity, and FACS was used to assess the cell distribution in the cell cycle. Moreover, the
expressions of cell cycle-related proteins were examined by Western blot.
Results: Both two shRNA sequences against USP39 could efficiently reduce its expression in TT cells. Knockdown of
USP39 significantly decreased cell proliferation and caused cell cycle arrest at G2/M phase. Moreover, G2/M
phase-associated proteins, Cyclin B1 and CDK1, were obviously down-regulated in TT cells after USP39 silencing.
Conclusions: Therefore, knockdown of USP39 is likely to provide a novel alternative to targeted therapy of MTC and
deserves further investigation.
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Medullary thyroid carcinoma (MTC) accounts for 5–10 %
of all thyroid cancers and carries a worse prognosis than
other differentiated thyroid cancers with an overall
10-year survival rate of 75–85 % [1, 2]. MTC is a
neuroendocrine tumor originating from the parafolli-
cular C cells of the thyroid gland [3]. Calcitonin and
carcinoembryonic antigen are useful blood markers
and are often used in patient’s follow-up. Although
the majority of MTC cases are sporadic, approximately
20 % are hereditary because of a germline mutation
in the rearranged during transfection proto-oncogene
(RET) [4–6]. Hereditary MTC can present in isolation
(familial medullary thyroid cancer (FMTC)) or as part* Correspondence: yuwang_dr@163.com
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(MEN2, MEN2A, or MEN2B). Patients with newly di-
agnosed disease are treated with surgery. A common
discovery in MTCs that is diagnosed late is lymph
node metastasis in the upper mediastinum and neck.
Metastases occur in ~70 % of patients with MTC
who have a palpable thyroid nodule (>1.0 cm diameter)
[7]. At this stage of the disease, patients cannot undergo
surgical resection and biochemical “cure” rates drop to
≤30 % [8, 9]. Therefore, systemic radiation and chemo-
therapy therapy are not believed to represent important or
useful options for most patients with MTC.
Ubiquitin-specific peptidase 39 (USP39) contains a
central zinc finger and two ubiquitin C-terminal hydro-
lase (UCH) domains. Interestingly, USP39 does not have
ubiquitin-specific peptidase activity but plays an essen-
tial role in pre-mRNA splicing as a component of the
U4/U6-U5 tri-snRNP, one of the building blocks of thedistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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nines, serines, and glutamic acids and resembles the RS
domain of serine/arginine (SR)-related proteins, which is
essential to recruit the tri-snRNP to the prespliceosome
[11]. USP39 has been implicated in the assembly of the
mature spliceosome complex [12]. USP39 is also re-
quired to maintain mitotic spindle checkpoint integrity
and support successful cytokinesis, probably through
splicing of Aurora B and other mRNAs that are essential
for proper spindle checkpoint function [13]. Depletion
of USP39 by RNAi induced massive polypoidization in
U2OS cells, possibly a result of defective chromosome
segregation and cytokinesis, suggesting USP39 as a key
regulator of mitosis. Recently, some studies have re-
ported the role of USP39 in cancer cell growth. Wang
et al. demonstrated that USP39 is expressed at a higher
level in breast cancer and regulates cell growth and sur-
vival [14]. Wen et al. demonstrated that the overexpres-
sion of USP39 could enhance the proliferation of prostate
cancer cells, suggesting that USP39 may also play a role in
prostate cancer development [15]. However, the involve-
ment of USP39 in MTC remains unclear.
The aim of this study was to explore the potential role
of USP39 in MTC cell growth. We carried out loss-of-
function analysis in one human MTC cell line TT using
lentivirus-delivered short hairpin RNA (shRNA) target-
ing USP39. After USP39 silencing, cell proliferation was
suppressed and cell cycle was arrested at G2/M phase.
Therefore, the inhibition of USP39 by shRNA might be a
potential therapeutic method in MTC.
Methods
Materials
F-12K medium was obtained from Gibco (Carlsbad, CA,
USA, cat no.21127022). DMEM was obtained from
Hyclone (Logan, UT, USA, cat no.SH30243.01B+). Fetal
bovine serum (FBS) was obtained from Biowest (Loire
Valley, France, cat no.S1810). Lipofectamine 2000 and
TRIzol® Reagent were purchased from Invitrogen (Carlsbad,
CA, USA). M-MLV Reverse Transcriptase was purchased
from Promega (Madison, WI, USA). All other chemicals
were obtained from Sigma-Aldrich (St. Louis, MO, USA).
The lentiviral vector (pFH-L) and packaging vectors
(pVSVG-I and pCMVΔR8.92) were purchased from
Shanghai Hollybio (Shanghai, China). The antibodies used
were as follows: rabbit anti-USP39 antibody (1:1000
dilution; Proteintech Group, Inc., cat no.23865-1-AP), p-
CDC2/CDK1(Tyr15) antibody (1:1000 dilution; Cell Signal-
ing Technology, cat no.9111), mouse anti-CDC2/CDK1
antibody (1:1000 dilution; Cell Signaling Technology, cat
no.9116), rabbit anti-GAPDH antibody (1:100,000 dilution;
Proteintech Group, Inc., cat no.10494-1-AP), and horse-
radish peroxidase-conjugated goat anti-rabbit (1:5000 dilu-
tion; Santa Cruz, cat no.SC-2054) secondary antibodies.Cell culture
Human MTC cells TT and human embryonic kidney
cells 293T were purchased from the Cell Bank of Chin-
ese Academy of Science (Shanghai, China). TT cells were
maintained in F-12K medium supplemented with 10 %
FBS. Maintained in DMEM supplemented with 10 %
FBS were 293T cells. These cell lines were cultured at
37 °C in humidified atmosphere of 5 % CO2.
Lentivirus-delivered short hairpin RNA transduction
Two shRNA sequences targeting human USP39 gene
(NCBI accession number: NM_001256725.1) were 5′-
GATTTGGAAGAGGCGAGATAACTCGAGTTATCTCG
CCTCTTCCAAATCTTTTT-3′ (S1) and 5′-CCTTCCA
GACAACTATGAGATCTCGAGATCTCATAGTTGTC
TGGAAGGTTTTT-3′ (S2), which were subjected to
BLAST analysis against the human genome database
to eliminate cross-silence phenomena with nontarget
genes. A scrambled fragment (5′-GCGGAGGGTTTG
AAAGAATATCTCGAGATATTCTTTCAAACCCTCC
GCTTTTTT-3′) that has no significant homology
with mouse or human gene sequences was used as a
negative control. The shRNAs were cloned into the
pFH-L vector by use of NheI/PacI restriction sites,
which was then transfected into 293T cells with packaging
vectors (pVSVG-I and pCMVΔR8.92) using Lipofecta-
mine 2000 according to the manufacturer’s instructions.
The supernatant was collected 48 h later, centrifuged
(4000 g, 4 °C, 10 min) to remove cell debris, filtered
through 0.45-μm cellulose acetate filters, and then con-
centrated again (4000 g, 4 °C, 15 min). TT cells were dis-
pensed into 6-well plates at a density of 150,000 cells per
well and transduced with shRNA-expressing lentivirus
(shCon or shUSP39(S1)/(S2)) at a multiplicity of infection
(MOI) of 60. The lentiviral vectors expressed green fluor-
escence protein (GFP), which allowed for measurement of
infection efficiency in transduced cells.
Quantitative real-time PCR analysis
TT cells were harvested after lentivirus transduction for
5 days. Total cellular RNA was extracted using Trizol re-
agent and reversely transcribed to cDNA by M-MLV re-
verse transcriptase according to the manufacturer’s
instructions. qPCR products were detected with SYBR
Green on BioRad Connect Real-Time PCR platform.
qPCR procedure was denatured at 95 °C for 1 min, 40 cy-
cles of denaturation at 95 °C for 5 s, and extension at
60 °C for 20 s. β-actin gene was amplified as internal
control. Relative quantitation was analyzed by taking the
difference ΔC(T) between the C(T) of β-actin and C(T)
of target gene and computing 2−ΔΔC(T). The following
primers were used: USP39, 5′-GCCAGCAGAAGAAAAA
GAGC-3′ (forward) and 5′-GCCATTGAACTTAGCCAG
GA-3′ (reverse); CCNB1 (Cyclin B1), 5′-CTGTTGGTT
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ATGTTGATCTTCG-3′ (reverse); β-actin, 5′-GTGGACA
TCCGCAAAGAC-3′ (forward) and 5′-AAAGGGTGTA
ACGCAACTA-3′ (reverse).
Western blotting analysis
TT cells were harvested after lentivirus transduction for
5 days. Total protein was extracted with 2× SDS Sample
Buffer (100 mM Tris–HCl (pH 6.8), 10 mM EDTA, 4 %
SDS, 10 % Glycine). Equal amounts of lysate (30 μg) in
each lane, as determined by the bicinchoninic acid
(BCA) assay, were separated by 10 % SDS-PAGE and
transferred to PVDF membranes. The membranes were
blocked with 5 % nonfat dry milk in Tris-buffered saline
with Tween 20 (TBST) for 1 h at room temperature and
incubated with TBST containing anti-USP39 or anti-
GAPDH antibody overnight at 4 °C, followed by incuba-
tion with secondary antibody for 1 h at room temperature.
The blots were detected using enhanced chemilumines-
cence (ECL) kit (Amersham) and visualized by exposure
to X-ray film. GAPDH was used as a control to verify
equal protein loading.
MTT assay
To evaluate the effect of USP39 on MTC cell prolifer-
ation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT) colorimetric assay was performed in TT
cells after lentivirus transduction for 4 days. Briefly, TT cells
were dispensed into 96-well plates at a concentration of
7000 per well. The plates were incubated for 1 to 5 days at
37 °C. On each day, 20 μL of MTT (5 mg/mL) was added
and incubated for 4 h. Afterwards, the entire supernatant
was discarded and acidic isopropanol (10 % SDS, 5 % iso-
propanol and 0.01 mol/L HCl) was added at a volume of
100 μL per well and incubated at 37 °C for 12 h. The
absorbance at 595 nm of each well was determined using
an ELISA reader.
Fluorescence-activated cell-sorting analysis
To evaluate the effect of USP39 on MTC cell cycle pro-
gression, flow cytometry assay was performed in TT cells
after lentivirus transduction for 6 days. Briefly, TT cells
were dispensed into 6-cm dishes at a concentration of
200,000 per dish. After culture at 37 °C for 40 h, cells were
harvested, fixed in 70 % ethanol, and stored overnight
at 4 °C. The cells were then treated with NaCl/Pi
staining solution (50 μg/mL PI and 100 μg/mL RNase
A). Following incubation for 1 h in the dark at room
temperature, cells were analyzed by flow cytometry
(FACSCalibur; Becton Dickinson, San Jose, CA, USA).
The fractions of the cells in G0/G1, S, and G2/M
phases were analyzed with dedicated software (Becton
Dickinson).Statistical analysis
Statistical analysis was performed using SPSS 16.0 soft-
ware package (SPSS Inc, Chicago, IL, USA). All data
were expressed as mean ± standard deviation (SD). Dif-
ferences between two groups were analyzed by Student’s
t test, and a p value of less than 0.05 was considered
statistically significant.
Results
Knockdown of USP39 expression with lentivirus-delivered
shRNA
TT cells were transduced with shRNA-expressing lenti-
virus (shCon or shUSP39(S1)/(S2)). GFP expression was
observed by fluorescent microscopy 4 days post-
transduction. As depicted in Fig. 1a, over 80 % of cells
expressed GFP in shCon, shUSP39(S1), and shUSP39(S2)
groups, indicating a successful infection rate. The inhibi-
tory effect of USP39 shRNA on its endogenous expression
in TT cells was examined by qRT-PCR and Western
blotting. As depicted in Fig. 1b, the mRNA level of
USP39 was significantly reduced in TT cells infected
with shUSP39(S1) with a knockdown efficiency of
73.9 %, in contrast to cells infected with shCon. Immuno-
blot further verified the down-regulation of USP39 ex-
pression at protein level (Fig. 1c). The mRNA level of
USP39 was also significantly reduced in TT cells infected
with shUSP39(S2) in contrast to cells infected with shCon
(Fig. 1d). Therefore, lentivirus-delivered shRNA could spe-
cifically deplete endogenous USP39 expression in TT cells.
Effect of USP39 knockdown on cell proliferation and cell
cycle progression
We next examined the effects of USP39 knockdown on
proliferation of TT cells. After infection of USP39
shRNA, MTT assay was performed in TT cells for five
consecutive days. As depicted in Fig. 2a, the number of
viable cells infected with shUSP39(S1)/(S2) was much
fewer than those infected shCon (p < 0.001). Besides, the
inhibitory effect was much stronger in shUSP39(S1)
group than in shUSP39(S2) group. This indicates that
knockdown of USP39 could strongly decrease the prolif-
eration of TT cells.
To test the mechanism by which USP39-modulating
cell proliferation, the flow cytometry assay was used to
determine the cell cycle of TT cells. Representative im-
ages of cell cycle distribution were presented as Fig. 2b.
As depicted in Fig. 2c, the cell percentage of G2/M
phase was increased from 14.29 ± 0.46 % in shCon-
infected cells to 19.85 ± 0.12 % in shUSP39(S1)-infected
cells. By contrast, the cell percentage of S phase was
decreased from 15.37 ± 0.63 % in shCon-infected cells to
7.54 ± 0.16 % in shUSP39(S1)-infected cells. This indi-
cates that USP39 shRNA could strongly block (p < 0.01)
the cell cycle progression of TT cells. Taken together,
Fig. 1 Lentivirus-delivered shRNA targeting USP39 depleted its endogenous expression in TT cells. a Evaluation of the lentivirus transduction rate,
which was more than 80 % as calculated by cellular enumeration using fluorescence and light microscopy. b Quantitative analysis of USP39
knockdown efficiency (S1) in TT cells was assessed by qRT-PCR. β-actin gene was used as an internal control. c Representative immunoblot showing
USP39 knockdown efficiency determined in TT cells. GAPDH protein was used as an internal control. d Quantitative analysis of USP39 knockdown
efficiency (S2) in TT cells was assessed by qRT-PCR. β-actin gene was used as an internal control. Each point represents the mean ± SD of three
independent repeats. The significance was determined by t test. **p < 0.01; scale bar, 10 μm
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inhibit TT cell proliferation by inducing G2/M phase cell
cycle arrest. As depicted in Fig. 2d, there is no significant
difference of Aurora B mRNA level between shCon-
infected cells and shUSP39(S1)-infected cells.
Effect of USP39 knockdown on G2/M-related cell cycle
regulators
In mammalian cells, G2/M transition is controlled by
cyclin-dependent kinase (CDK1) (also known as CDC2),
which partners with Cyclin B1. During G2 phase, the
CDK1/Cyclin B1 complex is held in an inactive state by
CDK1 phosphorylation at two negative regulatory sites,
threonine-14 (Thr14) and tyrosine-15 (Tyr15). There-
fore, we further examined the effect of USP39 knock-
down on the CDK1/Cyclin B1 complex. As depicted in
Fig. 3a, the mRNA level of Cyclin B1 was significantly
down-regulated in TT cells with the absence of USP39
(p < 0.05). Besides, both the phosphorylated and basal
levels of CDK1 were reduced by USP39 knockdown
(Fig. 3b). These results indicate that knockdown of
USP39 induced G2/M phase cell cycle arrest via sup-
pression of the CDK1/Cyclin B1 complex.Discussion
Spliceosome factors have been shown to be associated
with cancer development. For example, SF3B1 (Splicing
factor 3B subunit 1) is highly mutated in various
hematological malignancies such as chronic lymphocytic
leukemia and myelodysplastic syndromes [16, 17]. In this
study, we provided new evidence that USP39, a bona
fide spliceosome factor, is involved in the proliferation
regulation of MTC cells. Lentivirus-delivered short hair-
pin RNA (shRNA) targeting USP39 was used to stably
down-regulate its endogenous expression in MTC cells
TT. Knockdown of USP39 significantly inhibited pro-
liferation of TT cells in vitro. It has been shown that
USP39 is required to maintain the spindle checkpoint
and support successful cytokinesis [13]. Moreover, flow
cytometry analysis was performed to test the effect of
USP39 knockdown on mitosis. The cell cycle of TT cells
was arrested at G2/M phase with the absence of USP39,
which could contribute to the inhibition of cell prolifera-
tion. Our results were consistent with a previous research
showing that knockdown of USP39 markedly reduces the
proliferation of MCF-7 breast cancer cells [14], suggest-
ing that USP39 may play a role in cancer development.
Fig. 2 Knockdown of USP39 inhibited proliferation of TT cells. a MTT showing growth curves determined in TT cells. The number of viable cells
was much fewer in shUSP39(S1)/(S2) groups than in shCon group. b Comparison of the cell population in G0/G1, S, and G2/M phase between
shCon and shUSP39(S1) groups was assessed by flow cytometry. c The percentage of cells in G2/M phase was significantly higher in the
shUSP39(S1) group than in the shCon group, while the percentages of cells in S phase was simultaneously reduced. d Quantitative analysis of
Aurora B expression alteration in TT cells was assessed by qRT-PCR. β-actin gene was used as an internal control. Each point represents the mean ± SD
of three independent repeats. The significance was determined by t test. **p < 0.01
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vation and deactivation of CDK family proteins and Cyc-
lin complexes, such as CDK1/CyclinB complex, which
are associated with the entrance into mitosis, thereby,
regulating the G2/M transition. The phosphorylation of
Tyr15 of CDK1 suppresses activity of CDK1/CyclinB1
kinase complex [18]. In this study, the G2/M arrest
induced by USP39 knockdown was accompanied withFig. 3 Knockdown of USP39 down-regulates G2/M-related cell cycle regula
was assessed by qRT-PCR. β-actin gene was used as an internal control. b R
levels determined in TT cells. GAPDH protein was used as an internal contr
The significance was determined by t test. *p < 0.05the suppression of CDK1/CyclinB1 activity. Besides, RT-
PCR has been used to detect the Aurora B mRNA levels
(Fig. 1d), and there were significant differences of the
USP39 mRNA levels between shCon and shUSP39(S2)
groups, which demonstrated that the effect of USP39 in
MTC might not depend on the Aurora B.
Previous studies have reported that USP39 functions in
pre-mRNA splicing [12]. Therefore, further investigationstors. a Quantitative analysis of Cyclin B1 expression alteration in TT cells
epresentative immunoblot showing CDK1 and p-CDK1(Tyr15) protein
ol. Each point represents the mean ± SD of three independent repeats.
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of CyclinB and CDK1, as well as other genes that are
essential for cell cycle control.
Conclusions
In conclusion, knockdown of USP39 by RNAi inhibited
cell growth due to inactivation of the CDK1/CyclinB
complex. USP39 may play a critical role in MTC malig-
nant proliferation in vitro.
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